ESC 365 - Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection

Open Access

Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection

Session: Digitoxin and other therapeutic strategic advances

Topic: Pharmacotherapy

Speaker: Mr D. Ferreira (Lisbon, PT)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Mr Diogo Ferreira

Santa Maria Hospital - CHULN, Lisbon (Portugal)

0 follower

4 more presentations in this session

Effects of glucagon like peptide 1 receptor agonist initiation in patients with heart failure and reduced ejection fraction and implantable cardiac devices

Speaker: Doctor P. Marques (Porto, PT)

Real-world burden of heart failure with reduced ejection fraction and dapagliflozin use at 2 years after approval in 9 countries from Central Eastern Europe and Baltic Area: EVOLUTION-HF CEE-BA study

Speaker: Professor I. Gruev (Sofia, BG)

Safety and efficacy of early initiation of mineralocorticoid receptor antagonists in patients with worsening heart failure: a meta-analysis of randomized controlled trials

Speaker: Doctor R. Laborante (Rome, IT)

Socioeconomic disparities in guideline directed medical therapy for HFrEF: a population-based cohort study using electronic health records (the Netherlands)

Speaker: Ms J. van Eijk (Utrecht, NL)

Access the full session

Digitoxin and other therapeutic strategic advances

Speakers: Mr D. Ferreira, Doctor P. Marques, Professor I. Gruev, Doctor R. Laborante, Ms J. van Eijk

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources